"This award from the Emerging Technology Fund will allow Terapio to leverage the numerous university and industry collaborations we have within the State of Texas to accelerate the commercialization of the RLIP76 protein," said Curt Bilby, Terapio President and CEO and the current Chairman of BioAustin.
Curt Bilby, PhDDr. Curt Bilby, the President and CEO of Terapio since 2007, has over twenty years of executive leadership experience in the biotechnology, healthcare and information technology sectors both domestically and in Europe.Previously, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation which developed a biosensor based on technology developed at the Naval Research Laboratory.Prior to that, he was the Chairman and CEO of Evacyte Corporation, a company developing laser-based cancer detection and cell diagnostics using technology developed at The University of Texas at Austin.Dr. Bilby also served as the Président-Directeur Général of the multi-national company Eurimed, S.A. headquartered in Paris, France.Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin.Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.